Head-to-head evidence
Ametinib vs BEBT-109
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline
Ametinib
Developed by Hansoh Pharmaceutical Group and partners
NCT05754736 · Phase 2 · status unknown
This is a single-arm, open-label study with no comparator group, so there is no way to know whether the combination performs better than existing treatments. Results on tumor response and progression-free survival have not yet been posted.
BEBT-109
Developed by BeBetter Med
NCT06001671 · Phase 1 · completed
This was a small, single-arm, dose-escalation study with no control group and effectively no blinding of participants or investigators; it was designed to find a tolerable dose, not to test whether the drug worked, and results have not yet been reported.
Next expected readout: June 2027 · NCT06514027 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ametinib's landscape · BEBT-109's landscape